Healthcare & Life Sciences
Clotprotect Therapeutics
United Kingdom
seed
seed
Stage
1
Investors
About
Clotprotect Therapeutics is developing a first-in-class small-molecule direct plasmin inhibitor intended for intravenous administration to control fibrinolysis.
Explore Clotprotect Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.